Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells

The role of Kupffer cells (KCs) in the pathophysiology of the liver has been firmly established. Nevertheless, KCs have been underexplored as a target for diagnosis and treatment of liver diseases owing to the lack of noninvasive diagnostic tests. We addressed the hypothesis that cholesteryl ester t...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 62; no. 6; pp. 1710 - 1722
Main Authors Wang, Yanan, van der Tuin, Sam, Tjeerdema, Nathanja, van Dam, Andrea D., Rensen, Sander S., Hendrikx, Tim, Berbée, Jimmy F.P., Atanasovska, Biljana, Fu, Jingyuan, Hoekstra, Menno, Bekkering, Siroon, Riksen, Niels P., Buurman, Wim A., Greve, Jan Willem, Hofker, Marten H., Shiri‐Sverdlov, Ronit, Meijer, Onno C., Smit, Johannes W.A., Havekes, Louis M., van Dijk, Ko Willems, Rensen, Patrick C.N.
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer Health, Inc 01.12.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The role of Kupffer cells (KCs) in the pathophysiology of the liver has been firmly established. Nevertheless, KCs have been underexplored as a target for diagnosis and treatment of liver diseases owing to the lack of noninvasive diagnostic tests. We addressed the hypothesis that cholesteryl ester transfer protein (CETP) is mainly derived from KCs and may predict KC content. Microarray analysis of liver and adipose tissue biopsies, obtained from 93 obese subjects who underwent elective bariatric surgery, showed that expression of CETP is markedly higher in liver than adipose tissue. Hepatic expression of CETP correlated strongly with that of KC markers, and CETP messenger RNA and protein colocalized specifically with KCs in human liver sections. Hepatic KC content as well as hepatic CETP expression correlated strongly with plasma CETP concentration. Mechanistic and intervention studies on the role of KCs in determining the plasma CETP concentration were performed in a transgenic (Tg) mouse model expressing human CETP. Selective elimination of KCs from the liver in CETP Tg mice virtually abolished hepatic CETP expression and largely reduced plasma CETP concentration, consequently improving the lipoprotein profile. Conversely, augmentation of KCs after Bacille‐Calemette‐Guérin vaccination largely increased hepatic CETP expression and plasma CETP. Also, lipid‐lowering drugs fenofibrate and niacin reduced liver KC content, accompanied by reduced plasma CETP concentration. Conclusions: Plasma CETP is predominantly derived from KCs, and plasma CETP level predicts hepatic KC content in humans.(Hepatology 2015;62:1710–1722)
Bibliography:See Editorial on Page 1659
www.ctmm.nl
Potential conflict of interest: Prof. Riksen consults and received grants from AstraZeneca.
These authors contributed equally to this work
project PREDICCt (grant 01C‐104; to K.W.v.D.), the Center of Medical Systems Biology (CMSB), the Netherlands Consortium for Systems Biology (NCSB) established by The Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NGI/NWO), and "the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development and the Royal Netherlands Academy of Sciences" for the GENIUS project "Generating the best evidence‐based pharmaceutical targets for atherosclerosis" (CVON2011‐19), the Systems Biology Center for Metabolism and Aging (SBC‐EMA), the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) complementation project (grant BBMRI‐NL‐CP2013‐71), the Netherlands Organization for Scientific Research (NWO‐VIDI 864.13.013; to J.F.), and an unrestricted AstraZeneca grant to N.P.R.
This research was supported by the Dutch Heart Foundation (NHS grant 2007B81 [to P.C.N.R.], NHS‐Established Investigator 2009T038 [to P.C.N.R.], and NHS‐Dekker 2012T051 [to N.P.R.]), the Dutch Diabetes Research Foundation (DFN grant 2007.00.010; to P.C.N.R.), the Center for Translational Molecular Medicine (C.T.M.M.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0270-9139
1527-3350
1527-3350
DOI:10.1002/hep.27985